Home › Clinical Tools › Tumor markers

🎗️ Tumor Marker Interpretation

UseInterpret a marker as a monitoring trend in a diagnosed patient, not as a screening or diagnostic test.

Loading calculator…

SourceStandard clinical use and limitations of tumor markers

Runs locally in your browser (no PHI uploaded). For licensed clinicians — not a substitute for clinical judgement.
Stored on this device for revisit reminders

This-shift next steps

After scoring: open the scene pack, peer scores, and the matching pathway. Local reference — no HIS write.

Scene next step
📋oncoOpen scene pack →
Related scores
Matching pathway
🧭hypercalcemiaOpen pathway →
Score + version; reference only — not a substitute for care · no HIS write

Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.

Methodology · worked example, guidelines & full notes
Clinical takeaway

Most markers are for response/recurrence monitoring, not screening or diagnosis.

When to use

Interpret a marker as a monitoring trend in a diagnosed patient, not as a screening or diagnostic test.

How it works

Examples: CEA < 5 ng/mL, AFP < 10–20, CA19-9 < 37 U/mL, CA125 < 35 U/mL, PSA < 4 ng/mL.

Key points

  • Most markers are for response/recurrence monitoring, not screening or diagnosis.
  • The dynamic trend beats a single value.
  • Inflammation and benign disease commonly cause false positives.
  • An elevation must be confirmed with imaging and pathology.

References

Worked calculation

The values below come from this tool's own example placeholders and are computed server-side with the formula shown on this page, so the arithmetic can be checked quickly. It demonstrates how to substitute values only — it is not clinical advice and not a real case.

MarkerCA125

→MarkerCA125 (reference < 35 U/mL)

  • Associations：Epithelial ovarian cancer (monitoring)
  • False positives：Endometriosis, PID, menstruation, pregnancy, peritonitis, liver disease/ascites
  • Use：Mainly monitoring; adjunct for a postmenopausal pelvic mass
MarkerCEA

→MarkerCEA (reference < 5 ng/mL, higher in smokers)

  • Associations：Colorectal cancer (monitoring), gastric/pancreatic/lung/breast
  • False positives：Smoking, inflammatory bowel disease, liver disease, pancreatitis
  • Use：Response/recurrence monitoring, not screening
Verification & sources · governance
FAQ

Frequently asked questions

What are the limits and cautions when using Tumor Marker Interpretation?
For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.
Does Tumor Marker Interpretation upload patient data? Where is it calculated?
Calculation runs locally in the browser; inputs and results are not uploaded. For licensed clinicians only; interpret with history, investigations and local protocols — not a diagnosis or prescription.
How is Tumor Marker Interpretation calculated in practice? Can you show a worked example?
Inputs: Marker CA125 → Result: Marker CA125 (reference < 35 U/mL)（Associations: Epithelial ovarian cancer (monitoring), False positives: Endometriosis, PID, menstruation, pregnancy, peritonitis, liver disease/ascites, Use: Mainly monitoring; adjunct for a postmenopausal pelvic mass） Inputs: Marker CEA → Result: Marker CEA (reference < 5 ng/mL, higher in smokers)（Associations: Colorectal cancer (monitoring), gastric/pancreatic/lung/breast, False positives: Smoking, inflammatory bowel disease, liver disease, pancreatitis, Use: Response/recurrence monitoring, not screening）
Related tools

Other tools